Aswathy Asokan A N | Hematology | Best Scholar Award

Best Scholar Award

Aswathy Asokan A N — Amrita College of Nursing, India

Aswathy Asokan A N
Affiliation Amrita College of Nursing
Country India
Scopus ID 57219838768
Documents 18
Citations 376
h-index 11
Subject Area Hematology
Event Medical Lab Scientist Awards
ORCID 0009-0008-0020-5889

Aswathy Asokan is a nursing professional and researcher with interests in oncology, hematology, bone marrow transplantation, nursing education, and clinical innovation. Her academic profile reflects research involvement in clinical nursing, patient monitoring, and evidence-based healthcare practices. [1]

1. Abstract

Aswathy Asokan A N is a nursing researcher whose professional and academic interests include hematology, oncology, transplantation nursing, and healthcare innovation. Her research profile includes publications related to clinical monitoring and nurse-led approaches to patient assessment. Her work reflects the role of nursing research in improving clinical decision-making and patient care through structured evidence and technology-supported approaches.[1]

2. Keywords

Hematology, nursing research, oncology nursing, bone marrow transplantation, clinical monitoring, sepsis risk assessment, nursing education, patient care, clinical innovation.

3. Introduction

Nursing research contributes to healthcare development through the evaluation of clinical practices, patient safety strategies, and care delivery methods. Research in hematology and oncology nursing is particularly relevant to patients requiring specialized monitoring and supportive care. Aswathy Asokan’s academic interests connect nursing practice with clinical research and evidence-informed patient management.[2]

4. Research Profile

Her ORCID biography describes experience in oncology, hematology, and bone marrow transplantation, postgraduate training in Medical-Surgical Nursing, and doctoral studies in nursing. It also identifies professional involvement in nursing education, clinical manuals, transplant nursing, and clinical innovations. These areas provide context for her research and healthcare interests.[1]

5. Research Contributions

Her documented research includes work on nurse-led sepsis risk scoring and remote patient monitoring in adult febrile neutropenia. These topics explore clinical prediction approaches and structured monitoring in patients with complex hematological conditions. The research direction highlights nursing participation in risk assessment, early clinical recognition, and technology-supported care pathways.[3]

6. Publications

Her ORCID record lists publications including a study on development and internal validation of a nurse-led sepsis risk score using artificial intelligence-enabled remote monitoring in adult febrile neutropenia. It also lists a protocol concerning a nurse-led sepsis scoring system and a two-phase clinical prediction model using remote patient monitoring.[4]

7. Research Impact

Research involving clinical prediction models and remote monitoring may contribute to the evaluation of nursing assessment strategies and supportive care processes. Citation metrics and publication records offer quantitative indicators of scholarly activity, although they should be interpreted alongside publication quality, research context, collaboration, and clinical relevance rather than in isolation.[5]

8. Award Suitability

The Best Scholar Award recognizes scholarly engagement, research development, and contributions to an academic or professional discipline. Aswathy Asokan’s documented work in nursing research, hematology-related care, clinical monitoring, and research publications provides relevant material for consideration.

9. Conclusion

Aswathy Asokan A N’s profile reflects the intersection of nursing practice, specialized clinical care, and research innovation. Her publications concerning sepsis risk assessment and remote patient monitoring demonstrate an academic focus on clinically relevant nursing research. Her profile provides a basis for scholarly recognition within the nursing and hematology-related research community.

10. External Links

11. References

  1. ORCID. (n.d.). Aswathy Asokan A N: Researcher biography and works. ORCID Registry.
    https://orcid.org/0009-0008-0020-5889
  2. Rejikumar, G., Aswathy Asokan Ajitha, et al. (2023).Modeling Patient Perceptions About Generic Drug Quality and Trust With Doctors: An Empirical Analysis for Creating Sustainable Healthcare.
    https://doi.org/10.1109/TEM.2022.3208448
  3. Aswathy Asokan et al. (2026). Development and Internal Validation of a Nurse-Led Sepsis Risk Score Using AI-Enabled Remote Patient Monitoring Data in Adult Febrile Neutropenia: A Nested Case–Control Study. Diagnostics.
    https://doi.org/10.3390/diagnostics16223714
  4. Aswathy Asokan et al. (2026). Nurse-Led Sepsis Scoring System for Adult Febrile Neutropenia: Protocol for a Two-Phase Clinical Prediction Model Study With Remote Patient Monitoring. JMIR Research Protocols.
    https://doi.org/10.2196/107468
  5. Daneshfar, Z., Aswathy Asokan-Ajitha, et al. (2023).Work-from-home (WFH) during COVID-19 pandemic – A netnographic investigation using Twitter data.Information Technology & People.
    https://doi.org/10.1108/ITP-01-2021-0020

Firstca Rachma | Spectrophotometry | Best Researcher Award

Best Researcher Award

Firstca Rachma — Universitas Telogorejo Semarang, Indonesia

Firstca Rachma
Affiliation Universitas Telogorejo Semarang
Country Indonesia
Subject Area Spectrophotometry
Google Scholar Bd4TdW4AAAAJ
Citations 278
Documents 20
h-index 5
Event Name Medical Lab Scientist Awards

Firstca Rachma is a researcher. Her documented academic activities include pharmaceutical analysis, spectrophotometric methods, and investigations involving pharmaceutical research. Her publications provide a basis for examining her contributions to applied pharmaceutical sciences. [1]

1. Abstract

This article presents the academic profile and research activities of Firstca Rachma. Her identified research includes pharmaceutical analysis, UV-Visible spectrophotometry, and investigations into pharmaceutical products. Her published work provides evidence of research engagement in analytical and applied pharmacy. [1]

2. Keywords

Firstca Rachma; Best Researcher Award; Spectrophotometry; Pharmaceutical Analysis; Pharmacy Research; Analytical Chemistry; Universitas Telogorejo Semarang.

3. Introduction

Pharmaceutical research contributes to medicine quality, analytical accuracy, and evidence-based healthcare practices. Firstca Rachma’s research activities reflect these areas through published investigations involving analytical techniques and pharmaceutical applications. [2]

4. Research Profile

Affiliated with Universitas Telogorejo Semarang, Firstca Rachma has contributed to pharmacy-related academic publications. Her identified research record includes work on UV-Vis spectrophotometric analysis and pharmaceutical product investigations. [3]

5. Research Contributions

Her identified contributions include quantitative analysis of monosodium glutamate in instant noodles using UV-Vis spectrophotometry and research examining the cytotoxic activity of ethanol extract from soursop stem bark against T47D cells. [1]

6. Publications

Identified publications include the study on monosodium glutamate analysis, the investigation of soursop stem bark extract, and research evaluating acrylamide levels in roasted Arabica and Robusta coffee. These publications relate to analytical and pharmaceutical research. [2]

7. Research Impact

Her research addresses practical questions in pharmaceutical analysis and product evaluation. These subjects are relevant to analytical quality assessment and the responsible application of scientific methods. Citation metrics and overall research impact require independent database verification.

8. Award Suitability

The Best Researcher Award recognition profile considers documented publications, research relevance, and academic contributions. Firstca Rachma’s identified work provides material for evaluation within pharmaceutical sciences and spectrophotometry. Final eligibility and award selection remain subject to the event’s assessment criteria.

9. Conclusion

Firstca Rachma’s documented academic work demonstrates engagement with pharmaceutical analysis and applied research. Her publications provide a foundation for examining her research contributions through the Medical Lab Scientist Awards.

11. References

  1. Google Scholar. (n.d.). Firstca Rachma – Researcher Profile and Publications.
    https://scholar.google.com/citations?user=Bd4TdW4AAAAJ
  2. Rachma, F. A., Haryoto, & Indrayudha, P. (2020). Uji Efektifitas Sitotoksik Ekstrak Etanol Kulit Batang Sirsak terhadap Sel T47D. Jurnal Farmasi & Sains Indonesia, 3(2), 1–11.
    https://www.journal.stifera.ac.id/index.php/jfsi/article/view/49
  3. Juwariyah, P. S., Rachma, F. A., & Alighiri, D. (2026). Evaluation of Acrylamide Levels in Arabica (Coffea arabica) and Robusta (Coffea canephora) Coffee Roasting Variations for Nutraceutical Capsules. Journal of Food and Pharmaceutical Sciences, 14(2), 151–163.
    https://doi.org/10.22146/jfps.25012
  4. Garuda – Garba Rujukan Digital. (n.d.). Firstca Aulia Rachma – Author Profile and Indexed Publications.
    https://garuda.kemdiktisaintek.go.id/author/view/9952644

Hossein Nourani | Pathology | Best Researcher Award

Best Researcher Award

Hossein Nourani
Affiliation Ferdowsi University of Mashhad
Country Iran
Scopus ID 43561438900
Documents 54
Citations 397
h-index 10
Subject Area Pathology
Event Name Medical Lab Scientist Awards
ORCID 0000-0002-4035-1118

Hossein Nourani — Ferdowsi University of Mashhad, Iran

Hossein Nourani is an academic researcher. His scholarly activities encompass veterinary pathology, histopathological investigations and disease-related research. His academic profile documents research publications across several areas of veterinary and biomedical sciences. [1]

1. Abstract

This article presents the academic profile of Hossein Nourani and highlights his documented research activities in pathology and veterinary sciences. His publication record includes investigations involving infectious diseases, tissue abnormalities, histopathology and experimental studies. His academic recognition profile is presented in connection with the Best Researcher Award. [1]

2. Keywords

Hossein Nourani, Best Researcher Award, Veterinary Pathology, Histopathology, Pathological Research, Ferdowsi University of Mashhad, Medical Lab Scientist Awards.

3. Introduction

Pathology contributes to understanding disease mechanisms through the examination of tissues, organs and pathological changes. Research in this discipline supports diagnostic knowledge and scientific investigation. Nourani’s documented publications demonstrate engagement with veterinary pathological research and related biomedical subjects. [3]

4. Research Profile

According to his ORCID record, Nourani has been associated with the Faculty of Veterinary Medicine at Ferdowsi University of Mashhad since 2013 as an Associate Professor in the Department of Pathobiology. His academic record also identifies veterinary pathology as a research keyword. [1]

5. Research Contributions

His research contributions include studies of animal diseases, infectious conditions, organ pathology and histopathological changes. Published investigations address subjects such as bovine diseases, viral infections, parasitic conditions and tissue abnormalities, reflecting a broad range of veterinary pathology applications. [4]

6. Publications

Representative publications include research on avian mycobacteriosis, pathological findings in animal organs and viral envelope proteins. His recent work also addresses Neospora caninum infection and histopathological investigations. These publications demonstrate continuing scholarly activity across veterinary research topics. [5]

7. Research Impact

The Scopus profile reports 54 documents, 397 citations and an h-index of 10. These indicators provide quantitative information about publication activity and citation visibility. They should be interpreted alongside research quality, disciplinary context and individual scholarly contributions. [2]

8. Award Suitability

Nourani’s documented academic appointment, publication activity and research engagement provide relevant information for consideration under the Best Researcher Award category at the Medical Lab Scientist Awards. Final recognition should depend on the event’s eligibility requirements and independent evaluation criteria. [1]

9. Conclusion

Hossein Nourani’s academic profile reflects sustained involvement in veterinary pathology and related scientific investigations. His research publications, institutional affiliation and reported bibliometric indicators provide a documented foundation for presenting his academic contributions and professional recognition. [2]

11. References

  1. ORCID. (n.d.). Hossein Nourani – ORCID Researcher Record.
    https://orcid.org/0000-0002-4035-1118
  2. Elsevier. (n.d.). Scopus author details: Hossein Nourani, Author ID 43561438900. Scopus.
    https://www.scopus.com/authid/detail.uri?authorId=43561438900
  3. Salamatian, I., Ghaniei, A., Mosavari, N., Nourani, H., Keshavarz, R., & Eslampanah, M. (2020). Outbreak of avian mycobacteriosis in a commercial turkey breeder flock. Avian Pathology.
    https://doi.org/10.1080/03079457.2020.1740167
  4. Nourani, H., & Sadr, S. (2023). Diffuse and Massive Endocardial Sarcocystosis in a Lamb. Series of Cardiology Research.
    https://doi.org/10.54178/2768-5985.2022a3
  5. Nourani, H., & Pirali Kheirabadi, K. (2009). Cerebral coenurosis in a goat: Pathological findings and literature review. Comparative Clinical Pathology.
    https://doi.org/10.1007/s00580-008-0742-2

Guoping Zheng | Molecular Biology | Best Researcher Award

Best Researcher Award

Guoping Zheng — The University of Sydney, Australia
Guoping Zheng
Affiliation The University of Sydney
Country Australia
Scopus ID 8698483700
Documents 106
Citations 6,791
h-index 33
Subject Area Molecular Biology
Event Name Medical Lab Scientist Awards
ORCID 0000-0002-5551-4522

Guoping Zheng is a researcher, whose documented academic activities include molecular biology, renal medicine, immunology and kidney disease research. His ORCID record identifies an academic career at the University of Sydney and provides information about his education, employment and scholarly publications.[1]

1. Abstract

This article presents the academic profile and research activities of Guoping Zheng. His documented scholarly work includes kidney fibrosis, renal inflammation, immune regulation and molecular signalling. The ORCID record lists 76 works and records his professional and educational history. Scopus information for this profile reports 106 documents, 6,791 citations and an h-index of 33. [2]

2. Keywords

Guoping Zheng; Best Researcher Award; Molecular Biology; Renal Medicine; Kidney Fibrosis; Immunology; Cellular Signalling; Research Impact; Medical Laboratory Science.

3. Introduction

Research in molecular biology contributes to understanding cellular mechanisms associated with human disease. Guoping Zheng’s documented publications address biological pathways involved in kidney injury, inflammation and tissue fibrosis. These subjects connect molecular mechanisms with clinically relevant questions in renal medicine and biomedical research. [1]

4. Research Profile

According to his ORCID record, Zheng has been associated with the University of Sydney since 2007, holding research and academic appointments, including Associate Professor from 2019. His education includes a PhD from the University of Sydney and earlier medical and medical science qualifications from Shanxi Medical University. His recorded professional experience also includes appointments at Westmead Hospital. [1]

5. Research Contributions

His publication record covers several interconnected research themes, including renal fibrosis, inflammatory responses, dendritic cell activity and transforming growth factor-beta signalling. Studies involving beta-catenin and FoxO signalling investigate mechanisms associated with kidney tissue repair and fibrosis. [3]

6. Publications

Guoping Zheng’s ORCID record highlights research in renal interstitial fibrosis, kidney injury, and cellular signalling. His publications include Promotion of β-catenin/Foxo1 signaling ameliorates renal interstitial fibrosis (2019), and Matrix metalloproteinase 9 induces endothelial-mesenchymal transition via Notch activation in human kidney glomerular endothelial cells (2016). [4]

7. Research Impact

The Scopus profile reports 6,791 citations and an h-index of 33 across 106 documents. These indicators offer quantitative information about the visibility and citation history of the indexed research output. Citation measures should be interpreted with consideration of publication dates, subject-area practices and database coverage. [2]

8. Award Suitability

The Best Researcher Award recognizes scholarly contributions, research productivity and documented academic influence. Zheng’s publication history, research themes and bibliometric indicators provide relevant information for consideration within this recognition category. Final award eligibility and selection should be determined through the event’s published criteria and independent evaluation. [1]

9. Conclusion

Guoping Zheng’s academic record reflects sustained involvement in biomedical research, particularly in molecular mechanisms associated with kidney disease, inflammation and fibrosis. His documented appointments, publications and bibliometric profile provide a basis for presenting his research career in the context of the Medical Lab Scientist Awards. [2]

10. External Links

11. References

  1. ORCID. (2026). Guoping Zheng: ORCID researcher record and works.
    https://orcid.org/0000-0002-5551-4522
  2. Elsevier. (n.d.). Scopus author details: Guoping Zheng, Author ID 8698483700. Scopus.
    https://www.scopus.com/authid/detail.uri?authorId=8698483700
  3. Rao, P., et al. (2019). Promotion of β-catenin/Foxo1 signaling ameliorates renal interstitial fibrosis. Laboratory Investigation.
    https://doi.org/10.1038/s41374-019-0276-z
  4. Zhao, Y., et al. (2016). Matrix metalloproteinase 9 induces endothelial-mesenchymal transition via Notch activation in human kidney glomerular endothelial cells. BMC Cell Biology.
    https://doi.org/10.1186/s12860-016-0101-0
  5. Chen, T., et al. (2021). Conventional Type 1 Dendritic Cells (cDC1) in Human Kidney Diseases: Clinico-Pathological Correlations. Frontiers in Immunology.
    https://doi.org/10.3389/fimmu.2021.635212

Mohammed Ibrahim Saeed | Virology | Best Paper Award

Best Paper Award

Mohammed Ibrahim Saeed
Affiliation Gulf Medical University
Country United Arab Emirates
Scopus ID 56562469100
Documents 20
Citations 443
h-index 9
Subject Area Virology
Event Name Medical Lab Scientist Awards
ORCID 0000-0002-3530-1351

Mohammed Ibrahim Saeed — Gulf Medical University, United Arab Emirates

Mohammed Ibrahim Saeed is a researcher whose scholarly publication record includes work in virology, infectious diseases, vaccine research and molecular diagnostics. His research profile provides a basis for examining scientific contributions, publication activity and relevance to laboratory medicine. [1]

1. Abstract

Mohammed Ibrahim Saeed’s research profile encompasses virology, vaccine development, infectious disease investigation and molecular research. His publications address viral pathogenesis, hepatitis B, human metapneumovirus and vaccine-related immune responses. His documented scholarly activity provides relevant material for evaluating research quality and scientific contribution within the Best Paper Award category. [1]

2. Keywords

Mohammed Ibrahim Saeed; Virology; Vaccine Research; Infectious Diseases; Molecular Diagnostics; Hepatitis B; Viral Pathogenesis; Best Paper Award.

3. Introduction

Virology is an important research discipline addressing viral transmission, infection mechanisms, immune responses and disease prevention. Scientific contributions in this field support improved understanding of infectious diseases and the development of diagnostic and preventive approaches. Saeed’s publication record includes investigations relevant to these research priorities. [2]

4. Research Profile

Saeed is associated with Gulf Medical University, United Arab Emirates. His Scopus author identification and ORCID record provide researcher-level identifiers for examining his scholarly publications. The bibliometric information reports 20 documents, 443 citations and an h-index of 9. [1]

5. Research Contributions

His research contributions include investigations into viral infections, vaccine development and molecular characterization. These topics address important questions concerning disease mechanisms, immune protection and infectious disease monitoring. His work demonstrates the interdisciplinary relationship between virology, microbiology and laboratory-based biomedical research. [3]

6. Publications

Among his documented publications is the 2025 minireview, Designing next generation human metapneumovirus (HMPV) vaccine, published in Clinical and Experimental Vaccine Research. Other publications include research on hepatitis B e antigen as a predictor of hepatitis B virus DNA and investigations into Newcastle disease virus tissue tropism and pathogenesis. These studies illustrate the breadth of his documented contributions to viral disease research. [4]

7. Research Impact

Research impact can be examined through publication quality, citation activity, methodological contribution and relevance to scientific practice. The profile citation indicators provide quantitative context, while individual publications offer additional evidence of research themes and scholarly engagement. Bibliometric indicators should be interpreted alongside subject-specific considerations. [2]

8. Award Suitability

The Best Paper Award recognizes research papers demonstrating originality, scientific relevance, methodological strength and meaningful contributions to their respective disciplines. Saeed’s publications in virology and vaccine research provide relevant material for consideration. Final recognition should depend on the submitted paper, documented authorship, peer-reviewed evidence and the award committee’s evaluation criteria.

9. Conclusion

Mohammed Ibrahim Saeed’s scholarly record reflects research activity across virology, infectious diseases and vaccine development. His publications and researcher identifiers provide a foundation for academic assessment. His profile represents a relevant candidate for consideration within the Best Paper Award category of the Medical Lab Scientist Awards.

11. References

  1. ORCID. (2026). Mohammed Ibrahim Saeed: Researcher record
    https://orcid.org/0000-0002-3530-1351
  2. Elsevier. (n.d.). Scopus author details: Mohammed Ibrahim Saeed, Scopus.
    https://www.scopus.com/authid/detail.uri?authorId=56562469100
  3. Saeed, M. I. (2025). Minireview: Designing next generation human metapneumovirus (HMPV) vaccine. Clinical and Experimental Vaccine Research.
    https://doi.org/10.7774/cevr.2025.14.e12
  4. Hudu, S. A., Niazlin, M. T., Nordin, S. A., Saeed, M. I., et al. (2018). Quantitative hepatitis B e antigen: A better predictor of hepatitis B virus DNA than quantitative hepatitis B surface antigen. Clinical Laboratory.
    https://doi.org/10.7754/Clin.Lab.2017.170916
  5. Hussein, E. A., Hair-Bejo, M., Omar, A. R., Arshad, S. S., et al. (2019). Velogenic Newcastle disease virus tissue tropism and pathogenesis of infection in chickens by application of in situ PCR, immunoperoxase staining and HE staining. Microbial Pathogenesis.
    https://doi.org/10.1016/j.micpath.2019.02.017

Moumita Hazra | Pharmacology | Cancer Research Excellence Award

Cancer Research Excellence Award

Moumita Hazra — Hi-Tech Medical College and Hospital · India

Moumita Hazra
Researcher Moumita Hazra
Affiliation Hi-Tech Medical College and Hospital
Country India
Scopus ID 56500363800
Documents 3
Citations 119
h-index 3
Subject Area Pharmacology
Event Medical Lab Scientist Awards
Google Scholar ZHKN3KwAAAAJ

Moumita Hazra is researcher and her profile identifies in the context of pharmacology and medically relevant clinical research. The Research record lists publications addressing pharmacovigilance, rational pharmacotherapy, medication safety and clinical treatment comparisons.  [1]

Abstract

This profile summarizes the scholarly record of Moumita Hazra, whose listed work covers clinical pharmacology, pharmacoepidemiology and pharmacovigilance. The record includes studies of haematinics, topical acne therapies, asthma medication and metformin. These subjects relate to treatment effectiveness and medication safety, although the available evidence does not independently establish a cancer-specific research portfolio or award outcome. [1]

Keywords

Moumita Hazra, Cancer Research Excellence Award, pharmacology, clinical pharmacology, pharmacovigilance, rational pharmacotherapy, pharmacoepidemiology, medication safety and clinical research.

Introduction

Clinical pharmacology evaluates the use, safety and effects of medicines in patients. Pharmacovigilance and pharmacoepidemiology contribute to monitoring adverse effects and examining treatment patterns. Hazra’s listed publications include work in these areas, offering a relevant foundation for a profile centred on medicine-related research. [1]

Research Profile

The Google Scholar document identifies pharmacology and clinical pharmacology among Hazra’s research areas. Its listed publications include articles from the International Journal of Basic and Clinical Pharmacology and other medical journals. Institutional affiliation and bibliometric figures in the infobox are details and should be checked against current authoritative profiles. [2]

Research Contributions

The available publication list covers comparative medication studies, prescribing patterns and pharmacovigilance assessments. Examples include research concerning topical acne treatments, oral haematinics, asthma rescue medication and metformin. These subjects support a cautious description of contributions to clinical pharmacotherapy; a direct connection to oncology requires additional evidence. [1]

Publications

Examples in the record include a 2019 study of pharmacoepidemiology and pharmacohaemovigilance of iron preparations, a comparative study of topical anti-acne therapies, and research comparing arformoterol with salbutamol nebulisation. The record also lists work on metformin pharmacovigilance. [1]

Research Impact

Citation counts and h-index values are indicators of scholarly visibility, but they vary by database, indexing coverage and update date. The figures should not be interpreted as proof of clinical benefit or oncology expertise. The linked Google Scholar profile provides a route for checking the displayed publication list and citation information. [2]

Award Suitability

Consideration for the Cancer Research Excellence Award should depend on documented eligibility criteria and evidence of relevant cancer research, such as oncology publications, verified contributions or translational findings. Eligibility should therefore be assessed by the event organisers using verified supporting documents. [3]

Conclusion

Moumita Hazra’s scholarly record documents research related to pharmacology, medication safety and clinical treatment evaluation. These areas are relevant to medical research, but the available source does not establish a specific cancer research achievement or confirmed award. Further verification of oncology-related work and award criteria is necessary before making a stronger recognition claim.

References

  1. Google Scholar. (n.d.). Moumita Hazra: Author profile and listed publications.
    https://scholar.google.com/citations?user=ZHKN3KwAAAAJ&hl=en
  2. Elsevier. (n.d.). Scopus author details: Moumita Hazra, Scopus.
    https://www.scopus.com/authid/detail.uri?authorId=56500363800
  3. Medical Lab Scientist Awards. (n.d.). Event website
    https://medicallabscientist.com/
  4. Hazra, M. (2022). A systematic review on metformin rational pharmacotherapeutics. International Journal of Basic & Clinical Pharmacology, 11(4), 331–335
    https://doi.org/10.18203/2319-2003.ijbcp20221600
  5. Hazra, M. (2022). An analytical quantification clinical research, and an observational descriptive qualitative pharmacological research analysis on pharmacovigilance assessments of metformin monotherapy and combination therapies: A mixed-method study
    https://doi.org/10.5455/njppp.2022.12.03128202218052022

Behnaz Bayat | Immunohaematology | Women Researcher Award

Women Researcher Award

Behnaz Bayat — University of Giessen, Germany

Behnaz Bayat 
Affiliation University of Giessen
Country Germany
Scopus ID 22953143200
Documents 40
Citations 907
h-index 15
Subject Area Immunohaematology
Event Medical Lab Scientist Awards

Behnaz Bayat is a researcher. The academic recognition profile presents researcher information for Behnaz Bayat in the field of immunohaematology. The listed bibliometric indicators are attributed to the Scopus profile and should be checked against the current database record before publication.[1]

Abstract

The Women Researcher Award profile documents the academic affiliation and bibliometric indicators of Behnaz Bayat. Her stated subject area is immunohaematology, a discipline concerned with interactions between blood components and immune mechanisms. This page provides a structured overview for recognition-related information and independent verification.

Keywords

Behnaz Bayat, Women Researcher Award, immunohaematology, bibliometrics, Scopus, research recognition, Medical Lab Scientist Awards.

Introduction

Academic recognition can help communicate research activity and professional contributions. Responsible researcher profiles distinguish verifiable database information from interpretations, nominations, and award decisions. The information presented here is descriptive and does not independently establish award selection or endorsement.

Research Profile

The Research profile lists 40 documents, 907 citations, and an h-index of 15. These figures may change as publications are indexed and citation records are updated. Scopus author profiles can be consulted to verify author identity and associated publication metrics.[1]

Research Contributions

Immunohaematology encompasses the study of immune processes involving blood cells, antigens, and antibodies, including topics relevant to transfusion practice and laboratory investigation. Specific contributions by the researcher should be described using verified publications rather than inferred from subject classification alone.[2]

Publications

Behnaz Bayat has contributed to scientific research in immunohaematology, including studies on platelet immunology, blood group antigens, and transfusion-related immune responses. Her co-authored publications address antibody characterization, platelet interactions, and mechanisms associated with transfusion complications. These research contributions can be explored through the linked DOI records.

Research Impact

Citation counts and the h-index provide quantitative views of scholarly attention, but they do not independently measure research quality, clinical value, or societal benefit. Comparisons should consider disciplinary practices, career stage, database coverage, and publication type.[3]

Award Suitability

The profile is formatted for consideration in connection with the Women Researcher Award associated with Medical Lab Scientist Awards. Eligibility and selection should be assessed using the organizer’s published criteria, supporting evidence, and applicable review process. This profile alone does not confirm nomination, eligibility, or receipt of an award.

Conclusion

This page consolidates the professional and bibliometric details in a consistent academic format. Before publication, confirm the institutional affiliation, current metrics, researcher identity, and any award-related statements against reliable records. An ORCID identifier and verified publication references can be added when available.

References

    1. Elsevier. (n.d.). Scopus author details: Behnaz Bayat, Author ID 22953143200. Scopus.
      https://www.scopus.com/authid/detail.uri?authorId=22953143200
    2. Traum, A., Hofmann, C., Haas, S., Schmidt, S., Bein, G., Sachs, U. J., & Bayat, B. (2021). Characterization of CD177-reactive iso- and auto-antibodies. Transfusion.
      https://doi.org/10.1111/trf.16359
    3. Bayat, B., Nielsen, K. R., Bein, G., Traum, A., Burg-Roderfeld, M., & Sachs, U. J. (2021). Transfusion of Target Antigens to Pre-Immunized Recipients: A New Mechanism in Transfusion-Related Acute Lung Injury. Blood Advances, 5(20), 3975–3985.  https://doi.org/10.1182/bloodadvances.2020003843
    4. Santoso, S., Wihadmadyatami, H., Bakchoul, T., Werth, S., Al-Fakhri, N., Bein, G., Kiefel, V., Zhu, J., Bayat, B., et al. (2016). Antiendothelial αvβ3 Antibodies Are a Major Cause of Intracranial Bleeding in Fetal/Neonatal Alloimmune Thrombocytopenia. Arteriosclerosis, Thrombosis, and Vascular Biology.
      https://doi.org/10.1161/ATVBAHA.116.307281
    5. Korkmaz, B., Kuhl, A., Bayat, B., Santoso, S., Jenne, D. E., et al. (2009). A Hydrophobic Patch on Proteinase 3, the Target of Autoantibodies in Wegener Granulomatosis, Mediates Membrane Binding via NB1 Receptors. Journal of Biological Chemistry.  https://doi.org/10.1074/JBC.M806754200

Yong-Le Yang | Virology | Innovative Research Award

Innovative Research Award

Yong-Le Yang — Xianghu Laboratory, China

Yong-Le Yang
Affiliation Xianghu Laboratory
Country China
Scopus ID 57195945518
Documents 38
Citations 1,194
h-index 16
Subject Area Virology
Event Name Medical Lab Scientist Awards
ORCID 0000-0002-3266-8019

Yong-Le Yang is a researcher, whose ORCID record identifies virology as a research keyword and lists publications concerning animal coronaviruses, viral infection, molecular diagnostics and host-pathogen interactions. This article presents his research profile and selected publications in the context of the Innovative Research Award. [1]

Abstract

Yong-Le Yang’s research focuses on virology, with particular emphasis on animal coronaviruses, viral infection mechanisms, host–pathogen interactions, and molecular diagnostic approaches. His published studies investigate aspects of swine enteric coronavirus biology, including viral entry, protein function, and the development of laboratory detection methods. [1]

Keywords

Virology, animal coronaviruses, viral pathogenesis, molecular diagnostics, host-pathogen interactions, swine enteric viruses, research publications, citation analysis and scientific recognition.

Introduction

Virology examines viral structure, replication, transmission and interactions with host organisms. Research into animal coronaviruses contributes to understanding infection mechanisms and developing diagnostic approaches. Yang’s publications address several of these subjects, providing context for evaluating his research activities and scientific contributions. [2]

Research Profile

The profile reports 38 documents, 1,194 citations and an h-index of 16. These metrics provide quantitative information about publication and citation records, although values may change across databases and over time. His ORCID record lists Xianghu Laboratory and identifies virology among his research keywords. [1]

Research Contributions

Yang’s documented publications include research on swine acute diarrhea syndrome coronavirus, porcine deltacoronavirus, viral entry and molecular detection. These studies investigate mechanisms associated with infection and approaches to laboratory diagnosis. Together, the publications represent research activity across experimental virology and applied diagnostic investigation. [3]

Publications

Selected publications include a 2022 study of bile-acid-associated coronavirus entry in porcine intestinal enteroids, a 2022 article on multiplex real-time RT-PCR for swine enteric coronaviruses, and a 2020 review of swine enteric alphacoronavirus. These research topics contribute to the scientific understanding of emerging animal viruses and provide relevant evidence for further investigation into viral pathogenesis and diagnostic development. [4]

Research Impact

Citation counts and the h-index provide indicators of scholarly visibility but do not independently establish research quality or practical impact. Their interpretation should consider subject-specific citation patterns, publication dates, authorship contributions and the significance of individual findings. Verification against the relevant databases is recommended before formal assessment. [5]

Award Suitability

Yang’s documented research topics and bibliometric indicators may be considered when reviewing his suitability for the Innovative Research Award. A balanced evaluation should verify publication attribution, assess research originality and significance, and apply transparent eligibility criteria. This profile does not represent confirmation of award selection.

Conclusion

Yong-Le Yang’s research profile reflects activity in virology, particularly animal coronavirus research and diagnostic methods. His publication record and bibliometric indicators provide useful background for scholarly review. Any recognition decision should be based on verified evidence and consistent evaluation criteria.

References

  1. ORCID. Yongle Yang researcher record.
    https://orcid.org/0000-0002-3266-8019
  2. Yang, Y.-L., et al. (2022). Bile acids promote the caveolae-associated entry of swine acute diarrhea syndrome coronavirus in porcine intestinal enteroids. PLOS Pathogens.
    https://doi.org/10.1371/journal.ppat.1010620 
  3. Zhu, J.-H., et al. (2022). Development and Clinical Applications of a 5-Plex Real-Time RT-PCR for Swine Enteric Coronaviruses. Viruses.
    https://doi.org/10.3390/v14071536
  4. Yang, Y.-L., Yu, J.-Q., and Huang, Y.-W. (2020). Swine enteric alphacoronavirus: An update three years after its discovery. Virus Research.
    https://doi.org/10.1016/j.virusres.2020.198024
  5. Elsevier. Scopus author details: Yong-Le Yang, Author ID 57195945518.
    https://www.scopus.com/authid/detail.uri?authorId=57195945518

 

David Stejskal | Clinical Chemistry | Innovative Biomedical Research Award

Innovative Biomedical Research Award

David Stejskal
Affiliation Institute of Laboratory Medicine, University Hospital and Faculty of Medicine, Ostrava University
Country Czech Republic
Scopus ID 7005865420
Documents 213
Citations 3,995
h-index 30
Subject Area Clinical Chemistry
Event Medical Lab Scientist Awards
ORCID 0000-0003-1204-0395

David Stejskal is a Czech researcher and laboratory medicine specialist associated with the Institute of Laboratory Medicine at University Hospital Ostrava and the Faculty of Medicine of the University of Ostrava. His scholarly activity is situated principally within clinical chemistry, laboratory diagnostics, biomarker research and related biomedical disciplines.[1]

Abstract

This academic recognition profile summarizes the documented research activity of David Stejskal in clinical chemistry, laboratory medicine and biomedical research. His publication record encompasses diagnostic biomarkers, analytical and pre-analytical laboratory problems, cardiovascular biomarker research, neurodegenerative disease biomarkers and quantitative laboratory methodology.[1]

Keywords

Clinical chemistry, laboratory medicine, biomedical research, diagnostic biomarkers, clinical biochemistry, laboratory diagnostics, microRNAs, cardiovascular biomarkers, neurodegenerative disease biomarkers, analytical chemistry, chromatography, mass spectrometry, potassium measurement, laboratory interference, translational diagnostics, University Hospital Ostrava.[2]

Introduction

Clinical chemistry provides quantitative laboratory information that supports disease detection, differential diagnosis, monitoring and clinical decision-making. Contemporary laboratory medicine increasingly combines conventional biochemical testing with molecular biomarkers, advanced analytical technologies and rigorous assessment of factors that can influence laboratory results.[2]

Research Profile

David Stejskal is affiliated with the Institute of Laboratory Medicine in Ostrava, Czech Republic, with published research identifying connections to University Hospital Ostrava and the Faculty of Medicine at the University of Ostrava. His ORCID identifier, 0000-0003-1204-0395, provides a persistent scholarly identifier for author attribution and research discovery.[3]

Research Contributions

One component of Stejskal’s work concerns clinically important laboratory measurement and interpretation. A 2024 report on pseudonormokalemia examined circumstances in which serum potassium can appear to remain within a reference interval despite a substantially different plasma potassium concentration, particularly in the setting of thrombocytosis.[3]

Publications

David Stejskal’s research portfolio demonstrates broad contributions to laboratory medicine, clinical biochemistry, molecular biomarkers, and diagnostic research. His publications address important topics including pseudonormokalemia and potassium measurement, circulating microRNAs in heart failure, advanced mass-spectrometric quantification of insulin and insulin analogues, urinary fetuin-A in urolithiasis, and urinary N1,N12-diacetylspermine as a potential bladder-cancer marker.[4]

Research Impact

The supplied Scopus indicators report 213 indexed documents, 3,995 citations and an h-index of 30 for David Stejskal. In bibliometric terms, document count reflects indexed scholarly output, total citations indicate how frequently indexed publications have been cited by subsequent literature, and the h-index combines aspects of publication productivity and citation distribution.[4]

Award Suitability

For consideration under the Innovative Biomedical Research Award within the Medical Lab Scientist Awards, Stejskal’s documented profile presents several characteristics relevant to an academic evaluation. These include a substantial indexed publication record, sustained citation activity, research within clinical chemistry and laboratory medicine, participation in biomarker-oriented investigations and contributions to analytical and diagnostic methodology.[5]

Conclusion

David Stejskal’s academic profile reflects sustained activity in clinical chemistry, laboratory medicine and biomedical research. His documented work encompasses clinically relevant laboratory interpretation, molecular and biochemical biomarkers, neurodegenerative and cardiovascular research and advanced analytical methodology.[5]

References

  1. Elsevier. (n.d.). Scopus author details: David Stejskal, Author ID 7005865420. Scopus.
    https://www.scopus.com/authid/detail.uri?authorId=7005865420
  2. ORCID. (n.d.). ORCID record: David Stejskal, 0000-0003-1204-0395. ORCID.
    https://orcid.org/0000-0003-1204-0395
  3. Medical Lab Scientist Awards. (n.d.). Medical Lab Scientist Awards academic and scientific recognition platform.
    https://medicallabscientist.com/
  4. Chobolová, N., Švagera, Z., Stejskal, D., & Bužga, M. (2026). Candidate circulating microRNAs in patients with sarcopenic obesity: Results of a pilot screening. Biomedicines, 14(6), 1377.
    https://doi.org/10.3390/biomedicines14061377
  5. Zhang, X., Yeung, D. C. Y., Karpisek, M., Stejskal, D., Zhou, Z.-G., Liu, F., Wong, R. L. C., Chow, W.-S., Tso, A. W. K., Lam, K. S. L., & Xu, A. (2008). Serum FGF21 levels are increased in obesity and are independently associated with the metabolic syndrome in humans. Diabetes, 57(5), 1246–1253.
    https://doi.org/10.2337/db07-1476

Xiao Dong | Cancer | Innovative Research Award

Innovative Research Award

Xiao Dong
Affiliation Shanghai University
Country China
Scopus ID 56457039700
Documents 30
Citations 1,898
h-index 17
Subject Area Cancer
Event Medical Lab Scientist Awards
ORCID 0000-0001-6897-6999

Xiao Dong is a researcher associated with Shanghai University whose academic work includes cancer-related biomaterials, nanomedicine, tumor-responsive therapeutic systems, and cancer immunotherapy. His scholarly profile identifies research activity at the interface of biomedical materials, drug-delivery technology, tumor biology, and therapeutic innovation.[1]

Abstract

This academic recognition profile summarizes the research record of Xiao Dong in the broad subject area of cancer, with particular emphasis on biomedical materials, nanomedicine, tumor-responsive therapeutic platforms, and cancer immunotherapy. Recent published research associated with Dong includes the development of a hypochlorous acid-responsive prodrug nanoplatform designed to integrate tumor-responsive drug activation with immunotherapeutic mechanisms[1]

Keywords

Cancer, cancer immunotherapy, nanomedicine, biomaterials, tumor microenvironment, drug delivery, prodrug nanoplatform, tumor-responsive therapy, STING agonist, biomedical engineering, anticancer therapeutics, immune response, translational research, Shanghai University, medical research, therapeutic innovation.[2]

Introduction

Cancer research increasingly integrates molecular biology, immunology, materials science, pharmacology, and bioengineering to address challenges associated with treatment resistance, tumor heterogeneity, systemic toxicity, and the immunosuppressive tumor microenvironment. Nanomedicine represents one interdisciplinary approach in which engineered materials are investigated as carriers or responsive platforms for delivering therapeutic agents to tumors.[2]

Research Profile

Xiao Dong is associated with Shanghai University in China. Published work identifies affiliations that include Shanghai 411 Hospital/Shanghai University and the Institute of Artificial Intelligence and Biomanufacturing within the School of Medicine at Shanghai University. His ORCID identifier is 0000-0001-6897-6999, providing a persistent identifier for attribution and discovery of scholarly activity. [3]

Research Contributions

A notable component of Xiao Dong’s research concerns the application of engineered nanomedicine systems to cancer therapy. In a 2026 study published in Biomaterials Research, Dong and collaborators reported a hypochlorous acid-responsive prodrug nanoplatform for synergistic cancer immunotherapy. The experimental system combined a stimulus-responsive methylene blue–doxorubicin dimer prodrug with a stimulator of interferon genes agonist, with the objective of coordinating tumor-responsive therapeutic activity and antitumor immune stimulation. [3]

Publications

Hypochlorous Acid-Responsive Prodrug Nanoplatform for Synergistic Cancer Immunotherapy. Published in Biomaterials Research in 2026, this investigated a responsive prodrug nanoplatform combining chemotherapy-related mechanisms with immune activation for experimental cancer treatment.Tumor Metabolism-Rewriting Nanomedicines for Cancer Immunotherapy. [4]

Research Impact

The supplied Scopus indicators report 30 indexed documents, 1,898 citations, and an h-index of 17 for Xiao Dong. These figures indicate that a portion of the researcher’s indexed scholarly output has received citation attention from subsequent academic literature. The h-index represents a combined measure of publication productivity and citation distribution, while the total citation count describes citation reception across indexed documents. [4]

Award Suitability

For consideration under an Innovative Research Award in the subject area of cancer, Xiao Dong’s documented research record presents several academically relevant characteristics. These include participation in multidisciplinary cancer research, development and evaluation of tumor-responsive therapeutic platforms, integration of nanomedicine with immunotherapeutic mechanisms, and contribution to research examining biological barriers within the tumor microenvironment. [5]

Conclusion

Xiao Dong’s research profile reflects interdisciplinary work in cancer-related biomaterials, nanomedicine, tumor-responsive therapeutic systems, and cancer immunotherapy. Published research demonstrates engagement with strategies designed to combine targeted or stimulus-responsive drug activity with modulation of antitumor immunity.[5]

References

  1. Elsevier. (n.d.). Scopus author details: Xiao Dong, Author ID 56457039700. Scopus.
    https://www.scopus.com/authid/detail.uri?authorId=56457039700
  2. ORCID. (n.d.). ORCID record: Xiao Dong, 0000-0001-6897-6999. ORCID.
    https://orcid.org/0000-0001-6897-6999
  3. Medical Lab Scientist Awards. (n.d.). Medical Lab Scientist Awards academic and scientific recognition platform.
    https://medicallabscientist.com/
  4. Xia, S., Wang, X., Liu, C., Ji, R., Wang, M., Zhang, C., Chen, L., Chen, W., Yao, S. Q., Fang, C., & Dong, X. (2026). Hypochlorous Acid-Responsive Prodrug Nanoplatform for Synergistic Cancer Immunotherapy. Biomaterials Research, 30, Article 0300.
    https://doi.org/10.34133/bmr.0300
  5. Wang, X., Liu, C., Ji, R., Liu, J., Shao, Y., Xia, S., Li, J., Zhang, X., Luo, L., Wu, Y., Yao, S. Q., Fang, C., Chen, L., & Dong, X. (2026). Lipid droplet-targeted biomimetic liposomes potentiate chemo-ferroptosis therapy in leukemia. Advanced Materials.
    https://doi.org/10.1002/adma.202515716